BLMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BLMN is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows a mildly constructive short-term technical setup, but the fundamental picture remains mixed, Wall Street is still cautious overall, and there is no strong signal from Intellectia’s proprietary systems to override that. For an impatient buyer, this looks more like a hold than an immediate purchase.
The current price is 8.715, essentially flat versus the 8.7 previous close, with the broader market slightly negative. Technically, the stock is in a modest bullish phase: SMA_5 is above SMA_20 and SMA_200, which supports an upward trend. MACD histogram is positive at 0.0654, though it is contracting, suggesting momentum is improving but not accelerating strongly. RSI_6 at 54.08 is neutral, so the stock is not overbought. Key levels matter here: pivot is 8.584, with resistance at 9.146 and 9.492, and support at 8.022 and 7.676. Overall, trend is positive but not strong enough to call it a high-conviction entry.
["Recent analyst target increases from several firms, showing improved expectations around the turnaround.", "Q1 beat on same-store sales, revenue, and margins, plus raised Q2 guidance.", "Early Outback turnaround metrics and operational improvements such as better steak quality, staffing changes, and restaurant refresh efforts.", "Bullish technical structure with SMA_5 > SMA_20 > SMA_200."]
["JPMorgan downgraded the stock to Underweight and sees more attractive upside elsewhere in the sector.", "BofA keeps an Underperform rating, citing competitive intensity in steak as a limit on same-store sales growth.", "Analysts remain cautious that strategic improvements may take years to fully translate into shareholder value.", "No recent news in the last week and no strong catalyst-driven momentum.", "No significant hedge fund, insider, or congress trading support trends."]
No detailed latest-quarter financial snapshot was provided because of a data error, but the analyst commentary references a strong Q1 with beats on same-store sales, revenue, and margins, plus raised Q2 guidance. That implies improving near-term operating performance, especially in the latest reported quarter season, but the recovery still appears early-stage rather than fully established.
Wall Street is mixed to cautious. Several firms raised price targets on 2026-05-07 after improved Q1 results and better turnaround signs, including UBS, Citi, Goldman Sachs, Barclays, Deutsche Bank, and BofA. However, the ratings themselves remain mostly Neutral/Hold, with BofA Underperform and JPMorgan Underweight. The pros view is that the turnaround is showing early progress and valuation is undemanding; the cons view is that competition, pricing pressure, and execution risk still limit upside. Net-net, analysts see improvement but not a compelling long-term buy yet.
